DICER1 Mutations and Differentiated Thyroid Carcinoma: Evidence of a Direct Association.

J Clin Endocrinol Metab

Division of Endocrinology (M.M.R.), Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio 45229; PRIMA Pediatrics (P.J.), Cumberland, Rhode Island 02864; Division of Cancer and Blood Disorders (K.A.P.S., A.K.H.), Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota 55404; International Ovarian and Testicular Stromal Tumor Registry (K.A.P.S., A.K.H., D.A.H.), Minneapolis, Minnesota 55404; Waukesha County Medical Examiner's Office (A.S.), Waukesha, Wisconsin 53188; Division of Endocrinology and Diabetes (A.J.B.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104; Department of Pathology (A.L.F., D.A.H.), Children's National Medical Center and Center for Genetic Medicine Research, Children's Research Institute, Washington, DC 20010; and Division of Oncology (J.G.), Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio 45229.

Published: January 2016

Context: DICER1 germline mutation carriers have an increased predisposition to cancer, such as pleuropulmonary blastoma (PPB) and Sertoli-Leydig cell tumor (SLCT), and a high prevalence of multinodular goiter (MNG). Although differentiated thyroid carcinoma (DTC) has been reported in some DICER1 mutation carriers with PPB treated with chemotherapy, the association of DTC with DICER1 mutations is not well established.

Case Description: We report a family with DICER1 mutation and familial DTC without a history of chemotherapy. A 12-year-old female (patient A) and her 14-year-old sister (patient B) presented with MNG. Family history was notable for a maternal history of DTC and bilateral ovarian SLCT. Both sisters underwent total thyroidectomy. Pathological examination showed nodular hyperplasia and focal papillary thyroid carcinoma within hyperplastic nodules. Subsequently, patient A developed virilization secondary to a unilateral ovarian SLCT. During her evaluation, an incidental cystic nephroma was also found. Three other siblings had MNG on surveillance ultrasound examination; two had thyroidectomies, and one had two microscopic foci of papillary carcinoma. Patient A, her mother, and four affected siblings had a germline heterozygous pathogenic DICER1 mutation c.5441C>T in exon 25, resulting in an amino acid change from p.Ser1814Leu of DICER1. Somatic DICER1 RNase IIIb missense mutations were identified in thyroid nodules from three of the four siblings.

Conclusions: This family provides novel insight into an emerging phenotype for DICER1 syndrome, with evidence that germline DICER1 mutations are associated with an increased risk of developing familial DTC, even in the absence of prior treatment with chemotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701837PMC
http://dx.doi.org/10.1210/jc.2015-2169DOI Listing

Publication Analysis

Top Keywords

dicer1 mutations
12
thyroid carcinoma
12
dicer1 mutation
12
dicer1
10
differentiated thyroid
8
mutation carriers
8
familial dtc
8
ovarian slct
8
dtc
5
mutations differentiated
4

Similar Publications

Inhibition of immune checkpoint proteins is effective in adult cancers but has shown limited efficacy in pediatric cancers. While factors regulating expression of immune checkpoint proteins such as PD-L1 are well-documented in adult cancers, their regulation is poorly understood in pediatric cancers. Here, we show that PD-L1 is upregulated in distinct subsets of Wilms tumor, the most common pediatric kidney cancer.

View Article and Find Full Text PDF
Article Synopsis
  • The article addresses a specific correction related to the findings or data presented in the original research paper.
  • The DOI (Digital Object Identifier) indicates that this is a formal correction published in a scientific journal.
  • The correction likely aims to improve clarity or accuracy for readers referencing the original work.
View Article and Find Full Text PDF

To investigate the clinicopathological features, immunophenotype, molecular characteristics, and differential diagnosis of primary intracranial DICER1-mutant sarcoma in order to better understand this tumor type. A retrospective analysis was conducted on 7 cases of primary intracranial DICER1-mutant sarcoma diagnosed in the Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China between 2021 and 2023 using next-generation sequencing. At the same time, 10 gliosarcomas, 4 intracranial FET::CREB fusion-positive mesenchymal tumors, 4 malignant meningiomas, 3 malignant solitary fibrous tumors, 3 malignant peripheral nerve sheath tumors, 3 synovial sarcomas and 3 rhabdomyosarcomas (total 30 cases) were selected as control.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!